# EDGAR Filing Document

**Accession Number:** 0001438569
**File Stem:** 0001104659-26-043217
**Filing Date:** 2026-4
**Character Count:** 4525
**Document Hash:** 8e72c31762e8f6ec615175de10e922a7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-043217.hdr.sgml**: 20260414

**ACCESSION NUMBER**: 0001104659-26-043217

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260414

**FILED AS OF DATE**: 20260414

**DATE AS OF CHANGE**: 20260414

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Grifols SA
- **CENTRAL INDEX KEY:** 0001438569
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35193
- **FILM NUMBER:** 26861169

**BUSINESS ADDRESS:**
- **STREET 1:** 1585 BROADWAY
- **STREET 2:** SUITE 2376
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 212-969-3335

**MAIL ADDRESS:**
- **STREET 1:** 1585 BROADWAY
- **STREET 2:** SUITE 2376
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of April 2026**

**Commission File No. 001-35193**

**Grifols, S.A.**

(Translation of registrant's name into English)

**Avinguda de la Generalitat, 152-158**

**Parc de Negocis Can Sant Joan**

**Sant Cugat del Valles 08174**

**Barcelona, Spain**

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

**Grifols, S.A.**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **Item** | **Sequential Page Number** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[1.](#M_001) [Other Relevant Information](#M_001) | [3](#M_001) |

---

**Grifols, S.A.<br>** <br> Avinguda de la Generalitat 152-158<br> 08174 Sant Cugat del Vallès <br> Barcelona - ESPAÑA<br>Tel. [34] 935 710 500<br> Fax [34] 935 710 267<br>www.grifols.com

Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols, S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

**OTHER RELEVANT INFORMATION**

Grifols announces that it has concluded today a successful refinancing of its 2027 debt maturities by means of a credit agreement, in the form of a Term Loan B ("**TLB**"), structured in three tranches: (i) a term loan in US dollars with a principal amount of USD 2,000,000,000; (ii) a term loan in euros with a principal amount of EUR 1,250,000,000; and (iii) a revolving credit facility with a maximum available amount of USD 2,065,000,000.

The term loans will have a maturity of seven years from the date of execution of the agreement, whilst the revolving credit facility will have a maturity of six and a half years, subject to the conditions therein. The U.S. dollar TLB was set at SOFR (*Secured Overnight Financing Rate*) + 250 basis points with an OID (*Original Issue Discount*) of 99.25. The euro tranche was set at Euribor + 300 basis points with an OID of 99.75. Both the TLB and the Revolving Credit Facility benefit from leverage-based margin step-downs.

The proceeds obtained under the aforementioned financing will be used to (i) fully repay the outstanding loans under the existing 2019 TLB credit facilities, (ii) redeem and discharge the remaining outstanding amount under the existing 2019 Notes; (iii) to provide the Group with available liquidity for its development, supporting the simplification and extension of Grifols' debt maturity profile.

The refinancing together with the redemption of EUR 500,000,000 in aggregate principal amount of the existing April 2024 Notes made public yesterday, will strengthen the company's balance sheet by reducing funded gross debt levels, lowering cash interest expense, improving its debt maturity profile, whilst maintaining strong liquidity levels.

In Barcelona, on 14 April 2026

Laura de la Cruz Galán

Secretary to the Board of Directors

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
| Grifols, S.A. | Grifols, S.A. | Grifols, S.A. |
| By: | /s/ David I. Bell | /s/ David I. Bell |
|  | Name: | David I. Bell |
|  | Title: | Authorized Signatory |

---

Date: April 14, 2026